Azenosertib is named as a drug or biological intervention in 3 clinical trials in our USA and Ireland trial registers, 3 of which are recruiting. The lead sponsor is K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. Registered phases: Phase 3, Phase 2 and Phase 1. Conditions studied include Ovarian Cancer; High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer; Solid Tumor.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07546500 | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression (ClinicalTrials.gov ↗) Ovarian Cancer |
Phase 3 | Recruiting |
| NCT05128825 | A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (ClinicalTrials.gov ↗) High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
Phase 2 | Recruiting |
| NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer (ClinicalTrials.gov ↗) Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ovarian Cancer | 1 |
| High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | 1 |
| Solid Tumor | 1 |
| Epithelial Ovarian Cancer | 1 |
| Fallopian Tube Cancer | 1 |
| Peritoneal Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 3 |
| Register | Azenosertib trials |
|---|---|
| Clinical trials in USA | 3 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Azenosertib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Azenosertib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.